
Abeona Therapeutics Inc.: updates and filings
Price
$2.42
November 20, 2026Market cap $138M
What Ploutos Investor adds for Abeona Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 14 fiscal years, from 2010
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
November 2026
August 2026
June 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 18, 2026Shelf registration for future offeringsFormS-3
- Nov 16, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Nov 16, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Nov 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 12, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 9, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 9, 2026Results of operations, Regulation FD disclosureForm8-K
- Nov 9, 2026Material agreement entered, acquisition or disposal of assets, unregistered sale of shares, Regulation FD disclosureForm8-K
- Oct 23, 2026Over-5% holder statement (active)FormSCHEDULE 13D
- Sep 15, 2026Regulation FD disclosureForm8-K
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 13, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 13, 2026Results of operationsForm8-K
- Jun 26, 2026Shares registered for employeesFormS-8
- Jun 12, 2026Shareholder voteForm8-K
- Jun 12, 2026Officer or director changeForm8-K
- Jun 10, 2026Regulation FD disclosureForm8-K
- Jun 4, 2026Other material eventsForm8-K
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 13, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 13, 2026Results of operationsForm8-K
- May 4, 2026Additional annual meeting materialFormDEFA14A
- Apr 28, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Apr 27, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 18, 2026 | S-3 | Shelf registration for future offerings | Document |
| Nov 16, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Nov 16, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Nov 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 12, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 9, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 9, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Nov 9, 2026 | 8-K | Material agreement entered, acquisition or disposal of assets, unregistered sale of shares, Regulation FD disclosure | Document |
| Oct 23, 2026 | SCHEDULE 13D | Over-5% holder statement (active) | Document |
| Sep 15, 2026 | 8-K | Regulation FD disclosure | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 13, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 13, 2026 | 8-K | Results of operations | Document |
| Jun 26, 2026 | S-8 | Shares registered for employees | Document |
| Jun 12, 2026 | 8-K | Shareholder vote | Document |
| Jun 12, 2026 | 8-K | Officer or director change | Document |
| Jun 10, 2026 | 8-K | Regulation FD disclosure | Document |
| Jun 4, 2026 | 8-K | Other material events | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 13, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 13, 2026 | 8-K | Results of operations | Document |
| May 4, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 28, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Apr 27, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Aug 15, 1995.
The full analysis
What do Abeona Therapeutics's filings show?
The filings are where every one of Abeona Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.